Aspire Biopharma's BUZZ BOMB Receives Early Reviews For Fast-Acting Sublingual Pre-Workout Supplement Ahead Of August FITCON Launch

Early positive consumer testimonials from initial Company product sampling

Sublingual nano technology delivers caffeine rapidly to the bloodstream, bringing its unique benefits to the pre-workout market

Developed through over a decade of scientific research to deliver a patent-pending, fast-acting supplement formulation for maximum effect

Completed initial production in four flavors

Aspire to launch BUZZ BOMB™ at the FITCON and Fit Expo conventions in August

ESTERO, FL AND NEW YORK, NY / ACCESS Newswire / July 9, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending supplement delivery technology, today announced positive initial consumer feedback from the Company's sampling of its sublingual pre-workout supplement, BUZZ BOMB™. Featuring 50mg of caffeine and designed to support sustained energy and mental focus, BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout market to help athletes and fitness enthusiasts maximize their performance potential. Buzz Bomb™ provides nearly instant energy, in easy-to-use small sublingual packets, which can be taken right before and during work out as needed.

Last month, BUZZ BOMB™ began a soft launch of its product line, introducing it to strength trainers, consultants, and fitness professionals. Aspire sees BUZZ BOMB™ as more than just another supplement; it is a science-driven brand focused on understanding nutrition, performance, and the daily needs of athletes and fitness enthusiasts. BUZZ BOMB™ is a pre-workout solution that boosts endurance, energy metabolism, and overall performance, primarily through caffeine, a well-researched ingredient shown to enhance fitness results. Unlike pre-workout products that are mixed with water and taken well before a workout, BUZZ BOMB is sprinkled under the tongue for immediate effect.